Autopsy report · NCT01009515

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

“Low accrual; target accrual not met”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 5 years 10 months before it stopped.
• 19 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

New Mexico Cancer Research Alliance

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

Paclitaxel, carboplatin, temozolomide

Participants

19

Sites

3

Countries

United States

Trials that died the same way

• Registry to Compare Two Surgical Treatments for GERD
  “Unexpected low accrual” (80% match in meaning)
• Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
  “Accrual below target levels” (80% match in meaning)
• Facial Skin Health Tracking Feasibility in Breast Cancer Patients
  “Low/No Accrual” (78% match in meaning)
• Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
  “low accrual” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.